Skip to content

US · IMMX · BIOTECHNOLOGY

Immix Biopharma, Inc. (IMMX) intrinsic value and stock valuation

$6.96as of 2026-11-21 · Mkt cap 528.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immix Biopharma, Inc. DCF and intrinsic value

InvestorsCraft values IMMX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMMX’s statements →

Immix Biopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Los Angeles, CA 90064 immixbio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-29.44M
20192025
Free cash flow
-$-24.66M
20192025
Total equity
$93.8M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-27.21M-$-22.67M-$-16.14M-$-8.22M-$-1.35M
Net income-$-29.44M-$-21.61M-$-15.43M-$-8.23M-$-24.38M
EPSd-$-892.93K-$-763.87K-$-889.85K-$-592.51K-$-6.64M
Operating cash flow-$-23.93M-$-14.6M-$-11.37M-$-7.41M-$-1.59M
Capital expenditure-$-730K-$-1.18M-$-50K$0.00-$0.00
Free cash flow-$-24.66M-$-15.77M-$-11.42M-$-7.41M-$-1.59M
Total assets$104.8M$23M$19.9M$14.9M$18.2M
Total debt$1.07M$1.07M$0.00$0.00$50K
Net debt-$-92.86M-$-16.61M-$-17.51M-$-13.44M-$-17.59M
Total equity$93.8M$13.3M$16.2M$13.2M$18M
Cash and short-term investments$100.4M$17.7M$17.5M$13.4M$17.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$360K$0.00$0.00$0.00$0.00
Gross profit-$-360K$0.00$0.00$0.00$0.00
Research and development expenses$16.3M$11.3M$8.74M$4.2M$130K
Selling, general and administrative expenses$13.7M$11.4M$7.41M$4.02M$1.23M
Other expenses-$-3.11M$0.00$0.00$0.00$0.00
Operating expenses$26.9M$22.7M$16.1M$8.22M$1.35M
Cost and expenses$27.2M$22.7M$16.1M$8.22M$1.35M
Interest income$560K$1.02M$570K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$180K
Depreciation and amortization$360K$120K$10K$0.00$0.00
Ebitda-$-29.04M-$-21.54M-$-15.56M-$-8.22M-$-24.2M
Operating income-$-27.21M-$-22.67M-$-16.14M-$-8.22M-$-1.35M
Total other income/expenses, net-$-2.19M$1.02M$570K-$0.00-$-23.03M
Income before tax-$-29.4M-$-21.66M-$-15.57M-$-8.22M-$-24.38M
Income tax expense$40K$40K$30K$10K$10K
Net income-$-29.44M-$-21.61M-$-15.43M-$-8.23M-$-24.38M
Weighted average shares outstanding$33M$28.3M$17.3M$13.9M$3.67M
Weighted average diluted shares outstanding$33M$28.3M$17.3M$13.9M$3.67M
Balance sheet
20252024202320222021
Cash and short-term investments$100.4M$17.7M$17.5M$13.4M$17.6M
Net receivables$0.00$1.97M$1.17M$260K$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$101.2M$20.2M$19.8M$14.9M$18.2M
Property, plant and equipment, net$3.49M$2.73M$50K$0.00$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.6M$2.75M$140K$10K$10K
Total assets$104.8M$23M$19.9M$14.9M$18.2M
Accounts payable$5.44M$5.39M$1.43M$140K$140K
Short-term debt$140K$70K$0.00$0.00$50K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.1M$8.69M$3.72M$1.27M$200K
Long-term debt$930K$1.01M$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$930K$1.01M$0.00$470K$0.00
Capital lease obligations$1.07M$1.07M$0.00$0.00$0.00
Total liabilities$11M$9.7M$3.72M$1.75M$200K
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-104.46M-$-75.02M-$-53.41M-$-37.99M-$-29.76M
Accumulated other comprehensive income (loss)$60K-$0.00$130K$90K$130K
Total equity$93.8M$13.3M$16.2M$13.2M$18M
Total investments$6.48M$0.00$0.00$0.00$0.00
Total debt$1.07M$1.07M$0.00$0.00$50K
Net debt-$-92.86M-$-16.61M-$-17.51M-$-13.44M-$-17.59M
Cash flow statement
20252024202320222021
Net income-$-29.44M-$-21.61M-$-15.6M-$-8.23M-$-24.38M
Depreciation and amortization$360K$120K$10K$0.00$0.00
Stock-based compensation$2.44M$3.02M$2.57M$620K$220K
Change in working capital$2.7M$3.97M$1.65M$200K-$-390K
Accounts receivable$2.06M-$-970K-$-890K-$-240K$100K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.03M$4.4M$2.43M$1.13M-$-110K
Net cash provided by operating activities-$-23.93M-$-14.6M-$-11.37M-$-7.41M-$-1.59M
Investments in property, plant and equipment-$-730K-$-1.18M-$-50K$0.00-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-7.21M-$-1.18M-$-50K$0.00-$0.00
Common stock issued$107.4M$16M$15.7M$3.39M$18.7M
Common stock repurchased$0.00$0.00$0.00-$-100K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$107.4M$16M$15.5M$3.23M$18.9M
Net change in cash$76.3M$170K$4.07M-$-4.21M$17.3M
Cash at end of period$93.9M$17.7M$17.5M$13.4M$17.6M
Operating cash flow-$-23.93M-$-14.6M-$-11.37M-$-7.41M-$-1.59M
Capital expenditure-$-730K-$-1.18M-$-50K$0.00-$0.00
Free cash flow-$-24.66M-$-15.77M-$-11.42M-$-7.41M-$-1.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immix Biopharma, Inc.

        Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

        CEO
        Ilya Rachman
        Employees
        21
        Beta
        0.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Immix Biopharma, Inc. (IMMX)?

        InvestorsCraft does not currently publish an intrinsic value for IMMX. How the IC value is calculated.

        Is IMMX undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMMX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.